Asuragen Press Releases
2012
05-01-12 Data Presented at the Annual Meeting of the American Association of Endocrine Surgeons illustrates the clinical utility of miRInform® Thyroid Panel used in conjunction with Ultrasound-Guided Fine Needle Aspiration
03-30-12 Asuragen awarded $6.8 million commercialization award from the Cancer Prevention and Research Institute of Texas
03-22-12 FDA clears Asuragen’s RNARetain® Pre-analytical RNA Stabilization Device
02-17-12 Asuragen launches miRInform® Pancreas Test for Use on Fine Needle Aspirate Specimens of Pancreatic Masses
02-02-12 Life Technologies appoints Asuragen as a Certified Service Provider for Ion Torrent’s Personal Genome Machine
2011
11-15-11 Asuragen to Present at Upcoming Association for Molecular Pathology 17th Annual Meeting
11-3-11 Results of a Multi-center Study Show microRNA-based Pancreatic Cancer Assay Improves the Diagnostic Accuracy of FNA Cytology
11-3-11 MicroRNA Biomarkers in Cyst Fluid May Improve the Management of Pancreatic Cysts
10-31-11 Asuragen Launches BCR-ABL1 Calibrator Panels for IS Standardization
10-27-11 Asuragen Announces Launch of Xpansion Interpreter, a Test for AGG Mapping of
the Fragile X Gene, in its CAP Accredited CLIA Laboratory
9-27-11 Data from Evaluation of Signature® LTx Leukemia Test to be presented at
upcoming Planet XMAP
6-29-11 Asuragen and Fragile X Collaborators Report Findings using a Novel Methylation PCR Technology to Characterize the FMR1 Gene
5-24-11 Asuragen Announces New Notice of Allowance from USPTO Related to the Use of a miRNA as a Normalizer for miRNA Gene Expression Analysis
4-06-11 Asuragen announces launch of Inform™Thyroid Panel in its CAP Accredited CLIA Laboratory
3-31-11 Asuragen Announces Launch of its miRNA Biofluids Service for miRNA Analysis from Serum, Plasma, and more
3-23-11 Asuragen Launches CE Marked IVD AmplideX™ Fragile X Test in Europe
Asuragen Establishes International Distributor Network for its Molecular Diagnostics Products
3-16-11 Asuragen Reports Results from a Multi-Center Study on Fragile X Gene Expansion Risk at the Annual Meeting of the American College of Medical Genetics
1-12-11 Asuragen Announces New Notices of Allowance from USPTO Related to the Diagnostic Applications of Cancer-Related miRNAs at the JP Morgan Healthcare Conference
2010
12-06-10 Asuragen announces Collaboration on the development of BCR-ABL1 RNA IS Calibrators and Laboratory Software Reporting Tool at ASH
11-16-10 Asuragen to present at upcoming Association for Molecular Pathology 16th Annual Meeting
11-10-10 Asuragen Reports Notice of Allowance from USPTO Related to the Diagnostic Application of an Important Cancer-Related miRNA
09-23-10 Johns Hopkins Researchers Publish Results of Study Evaluating Multiplex Assay for Detection of Common NPM1 Mutations
09-01-10 Asuragen’s Clinical Laboratory launches KRAS and BRAF mutation testing
07-26-10 Asuragen and Collaborators Report Results Using PCR-only Technologies for the Comprehensive Molecular Assessment of the Fragile X Gene
07-13-10 Asuragen and Life Technologies Launch CE-Marked BCR/ABL1 Quant™ Leukemia Test in Europe
06-02-10 Asuragen Licenses BRAF Mutation for Molecular Diagnostic Testing
03-30-10 Asuragen Appoints Lyle Arnold, Ph.D., to Board of Directors
03-22-10 Asuragen Appoints French Distributor BioMedical Diagnostics SA for Signature® Oncology Portfolio
03-02-10 Asuragen and the UC Davis M.I.N.D. Institute Publish Results of a Study Evaluating a Novel Fragile X PCR Assay
02-18-10 Affymetrix and Asuragen Sign Agreement to Supply RNA Control Kits
for Molecular Diagnostic Applications
02-01-10 Asuragen Establishes Multi-Center Collaborations with Key Researchers for
Development of Diagnostic Test for Pancreatic Cancer
2009
12-16-09 Asuragen’s CLIA Laboratory Receives Accreditation from
College of American Pathologists
11-19-09 Asuragen to present at Association for Molecular Pathology
15th Annual Meeting
11-18-09 Asuragen Signs Development and Worldwide Distribution
Agreement with Life Technologies
10-07-09 Asuragen awarded more than $3.8 million in new NIH Small
Business grants
07-20-09 Asuragen signs agreement with Biogen Idec to pursue companion
diagnostic strategy
06-15-09 Mirna Therapeutics presents data at Keystone Symposium
on MicroRNA and Cancer
03-17-09 Agilent Technologies Appoints Asuragen, Inc. as a Certified
Service Provider for its aCGH and miRNA Microarrays
02-3-09 Mirna Therapeutics and UCSF Researchers Initiate Collaboration
to Explore Therapeutic Potential of microRNAs
01-28-09 Mirna Therapeutics to Collaborate with M. D. Anderson
on miRNA Prostate Cancer Therapeutics
2008
12-5-08 Asuragen Initiates Launch of CE-Marked Molecular Diagnostic
Products with the Release of the Signature® LTx v2.0 Leukemia Translocation Panel
Assay in Europe
12-1-08 Asuragen, Inc. Launches a Multiplex qRT-PCR Assay for the
Detection of BCR/ABL1 Fusion Transcripts
11-13-08
Applied Biosystems Launches Service Provider Program for Real-Time RNA Expression
Analysis
11-12-08
Applied Biosystems and Asuragen Collaborate with the Critical Path Institute to
Improve Drug Toxicity Screening
10-22-08 Asuragen Adds NuGEN Ovation® Systems to Gene Expression
Profiling Menu for RNA Amplification and Target Preparation
09-09-08 Asuragen® Signs Armored RNA® Licensing Agreement
with Focus Diagnostics
08-18-08 Asuragen, Inc. Launches Signature® NPM1 Mutations (RUO)*:
A Rapid Multiplex Assay for the Detection of NPM1 Mutations
07-08-08 Affymetrix and Asuragen Sign Agreement to Develop IVT
Reagent Kits for Molecular Diagnostic Applications
06-23-08 Asuragen to present study results on differentially expressed
microRNA biomarkers in pancreatic FNA and FFPE specimens, which can distinguish
benign from malignant tissues at the Annual Meeting of the European Pancreatic Club
in Poland
05-14-08
Asuragen Launches RNARetain™, as a CE-marked In-Vitro Diagnostic Device
04-23-08 Asuragen Launches Signature® LTx (Leukemia Translocation
Panel) Globally
04-23-08 Asuragen Launches The First Validated microRNA Diagnostic
Assay
03-31-08 Asuragen launches Mirna Therapeutics to Develop and Commercialize
microRNA Oncology Therapeutics
03-25-08 Yale and Asuragen Scientists Show that a microRNA Can
Reduce Lung Cancer Growth
01-03-08 Asuragen to Present at the JPMorgan 26th Annual Healthcare
Conference
2007
12-19-07 Asuragen introduces Four New microRNA Services
12-10-07 Asuragen, Inc. Raises $18.5 Million in Series B Financing
10-29-07 Xenomics Announces License with Asuragen for NPM1 Leukemia
Diagnostics
10-23-07 Asuragen Enters Oncology Collaboration with Merck to Develop
Pharmacogenomic Tests
10-08-07
Asuragen Licenses Roche’s Real-time Quantitative PCR Technology for Clinical Gene
Expression Profilinge
08-29-07 Asuragen to Present at the Thomas Weisel Partners Healthcare
Conference
08-02-07 Asuragen Launches Powerful New miRNA Analysis Tool
05-29-07
Asuragen, Inc. to provide GLP laboratory testing services to aid a Leading Biotechnology
Organization
04-16-07
Agendia accesses Asuragen’s proprietary pre-analytical solution for tissue preservation...
01-10-07
Asuragen Becomes the First Certified Service Provider for Illumina Gene Expression
Profiling
01-09-07
Asuragen Enters Into Licensing Agreement with Yale for Therapeutic Use of let-7
miRNA
01-03-07
Asuragen to Present at the JPMorgan 25th Annual Healthcare Conference
2006
12-14-06
Asuragen, Inc. Achieves ISO 13485 and ISO 9001 Certification
09-11-06
Asuragen Joins Industry Leaders in Completion of the FDA MAQC Project
08-16-06
Asuragen’s microRNA Expression Profiling Service Offers Sanger miRBase 8.0 Plus
New Proprietary Content
07-27-06
Asuragen Announces MicroRNA Co-Exclusive License Agreement with Max Planck Society
07-26-06
Asuragen Secures MicroRNA Licensing Agreement with Rockefeller University
06-01-06
Newly Launched Asuragen Closes Series A Funding of $49 Million